Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.
- Resource Type
- Article
- Source
- RMD Open; Feb2022, Vol. 8 Issue 1, p1-12, 12p
- Subject
- Language
- ISSN
- 20565933